Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory ly

Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory ly

Item
http://www.wikidata.org/entity/Q54316519
Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and PerspectivesMantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsPhase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: therapeutic horizons.Recent advances in targeting mTOR signaling pathway using small molecule inhibitors.mTORC1 and mTORC2 in cancer and the tumor microenvironment.Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma.The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors.A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors.
P2860

Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory ly

Item
http://www.wikidata.org/entity/Q54316519
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Efficacy, safety, pharmacokine ...... with relapsed or refractory ly
@en
Efficacy, safety, pharmacokine ...... with relapsed or refractory ly
@nl
type
label
Efficacy, safety, pharmacokine ...... with relapsed or refractory ly
@en
Efficacy, safety, pharmacokine ...... with relapsed or refractory ly
@nl
prefLabel
Efficacy, safety, pharmacokine ...... with relapsed or refractory ly
@en
Efficacy, safety, pharmacokine ...... with relapsed or refractory ly
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Efficacy, safety, pharmacokine ...... with relapsed or refractory ly
@en
P2093
P2860
P304
P31
P356
10.3109/10428194.2014.974040
P433
P478
P50
P577
P698